by hzhang | Aug 6, 2024 | Press Releases
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of...
by hzhang | Mar 6, 2024 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology March 6, 2024: Nature Biotechnology, a transformative journal covering the science and...
by hzhang | Oct 26, 2023 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium NEW YORK, October 26, 2023 – SEED Therapeutics Inc. (“SEED”), a...
by hzhang | Oct 23, 2023 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law...
by Brian K Carson | Jun 23, 2023 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors New York, NY – June 20, 2023 – SEED Therapeutics (the “Company”), a BeyondSpring (NASDAQ: BYSI) subsidiary...
by Brian K Carson | Jul 1, 2022 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania. King of Prussia, PA – July 01, 2022...
Recent Comments